Skip to main content

Cytovene (gancyclovir)

Audience: Pharmacists, other healthcare professionals

Healthcare professionals advised of a critical shortage of Cytovene-IV, indicated for the treatment or prevention of cytomegalovirus (CMV) disease. This shortage in supply is expected to last through the second quarter of 2002. Roche urges physicians to explore alternative treatment therapies or management strategies for their patients. This temporary situation affects only the IV formulation of Cytovene.

UPDATED:
[March 13, 2002 Letter - Roche]

[Feb 13, 2002 Letter - Roche]

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.